1. Prognostic value of MET copy number gain in non-small-cell lung cancer: an updated meta-analysis
- Author
-
Hyeong Su Kim, Bum Jun Kim, and Jung Han Kim
- Subjects
0301 basic medicine ,Oncology ,medicine.medical_specialty ,Met amplification ,Cochrane Library ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Medicine ,Lung cancer ,Prospective cohort study ,business.industry ,Hazard ratio ,medicine.disease ,Confidence interval ,meta-analysis ,030104 developmental biology ,non-small-cell lung cancer ,030220 oncology & carcinogenesis ,Meta-analysis ,MET copy number ,Adenocarcinoma ,business ,MET amplification ,Research Paper - Abstract
The alterations of MET have been detected in non-small-cell lung cancer (NSCLC). However, the prognostic impact of MET gene copy number gain (CNG) has not been consistent among studies. We performed this meta-analysis to evaluate the prognostic value of high MET CNG in patients with NSCLC. A systematic computerized search of the electronic databases including PubMed, EMBASE, Google scholar, and Cochrane Library (up to November 2017) was carried out. From twenty-one studies, 7,647 patients were included in the pooled analysis of hazard ratios (HRs) with 95% confidence intervals (CIs) for disease-free survival or overall survival. Compared with patients with NSCLC showing low MET CNG, those with tumors harboring high MET CNG showed significantly worse survival (HR = 1.45, 95% CI: 1.16-1.80, p = 0.001). Subgroup analyses showed that high MET CNG significantly correlated with a poor prognosis especially in patients with adenocarcinoma (HR = 1.41, 95% CI: 1.11-1.79, p = 0.005) and Asian populations (HR = 1.58, 95% CI: 1.32-1.88, p < 0.00001). In conclusion, this meta-analysis indicates that high MET CNG is an adverse prognostic factor in patients with NSCLC. Subgroup analyses suggest that high MET CNG is associated with a worse prognosis, especially in patients with adenocarcinoma and Asian populations. However, large prospective studies using standardized methods based on the homogeneous populations are warranted to validate the prognostic value of MET amplification in patients with NSCLC.
- Published
- 2018